Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.

Steven R LentzKaan KavakliRobert KlamrothMudi MisgavAzusa NagaoAlberto TosettoPernille Juul JørgensenMarek ZakLaszlo Nemes

Published in: Research and practice in thrombosis and haemostasis (2022)

Long-term prophylactic use of N8-GP appeared safe and efficacious across all age groups in people with severe hemophilia A previously treated with N8-GP.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
early onset
prognostic factors
peritoneal dialysis
patient reported outcomes